Autor: |
Lazaros, Lazaridis, Elisabeth, Bumes, Dorothee, Cäcilia Spille, Tim, Schulz, Sina, Heider, Sarina, Agkatsev, Teresa, Schmidt, Tobias, Blau, Christoph, Oster, Jonas, Feldheim, Walter, Stummer, Almuth Friederike, Kessler, Clemens, Seidel, Oliver, Grauer, Peter, Hau, Ulrich, Sure, Kathy, Keyvani, Ulrich, Herrlinger, Christoph, Kleinschnitz, Martin, Stuschke, Ken, Herrmann, Cornelius, Deuschl, Stella, Breuer, Elke, Hattingen, Björn, Scheffler, Sied, Kebir, Martin, Glas |
Rok vydání: |
2022 |
Zdroj: |
Neuro-oncology advances. 4(1) |
ISSN: |
2632-2498 |
Popis: |
The randomized phase 3 CeTeG/NOA-09 trial assessed whether CCNU plus temozolomide was superior to temozolomide alone in newly diagnosedWe retrospectively collected clinical and radiographic data from adult newly diagnosedSeventy patients were included. Median progression-free survival was 14.4 months and median overall survival 33.8 months. Patients with TTFields treatment for at least 8 weeks and CCNU plus temozolomide (The results from this multicentric trial indicate that-under real-life conditions-toxicity and survival estimates are comparable to the CeTeG/NOA-09 trial. TTFields therapy for at least eight weeks in combination with this regimen was independently associated with prolonged survival. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|